Transplantation for Aggressive Adult T-Cell Leukemia/Lymphoma (ATL)

  • Atae Utsunomiya


Adult T-cell leukemia-lymphoma (ATL) is an intractable disease, even with various chemotherapeutic agents. Curative treatment has been achieved for some ATL patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Transplant-related mortality (TRM) caused by myeloablative conditioning is higher than that with reduced-intensity conditioning, but the relapse rate is lower. The outcomes of ATL patients who received a transplant while in complete remission (CR) are better than those of patients in non-CR, or than patients transplanted from HLA-mismatched donors. The outcomes of ATL patients who underwent cord blood transplantation (CBT) were previously reported to be poor, but more recent outcomes are improved. The cessation of immunosuppressants and/or donor lymphocyte infusion induced another remission in some relapsed ATL patients after allo-HSCT; these phenomena were thought to be graft-versus-ATL effects. Donor cell-derived ATL has been reported in two patients, and special attention should be paid to this complication. The establishment of allo-HSCT with low TRM combined with immunotherapy or molecular targeting therapy should improve the cure rate of ATL patients in the near future.


Adult T-cell leukemia-lymphoma (ATL) Human T-cell leukemia virus type I (HTLV-1) Hematopoietic stem cell transplantation Graft-versus-ATL effect Donor cell-derived ATL 



This work was supported in part by the Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development, AMED.


  1. 1.
    Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50:481–92.PubMedGoogle Scholar
  2. 2.
    Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A. 1980;77:7415–9.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Hinuma Y, Nagata K, Hanaoka M, et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A. 1981;78:6476–80.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014;15:e517–26.CrossRefPubMedGoogle Scholar
  5. 5.
    Utsunomiya A, Choi I, Chihara D, Seto M. Recent advances in treatment of adult T-cell leukemia-lymphomas. Cancer Sci. 2015;106:344–51.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Utsunomiya A, Nakano N, Takatsuka Y. Recent advances in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma. J Hematopoietic Cell Transplant. 2015;4:1–8.CrossRefGoogle Scholar
  7. 7.
    Kuwazuru Y, Hanada S, Furukawa T, et al. Expression of P-glycoprotein in adult T-cell leukemia cells. Blood. 1990;76:2065–71.PubMedGoogle Scholar
  8. 8.
    Ohno N, Tani A, Uozumi K, et al. Expression of functional lung resistance-related protein predicts poor outcome in adult T-cell leukemia. Blood. 2001;98:1160–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Asou N, Sakai K, Yamaguchi K, et al. Autologous bone marrow transplantation in a patient with lymphoma type adult T cell leukemia. Rinshoketsueki. 1985;26:229–33.Google Scholar
  10. 10.
    Tsukasaki K, Maeda T, Arimura K, et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. Bone Marrow Transplant. 1999;23:87–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Sobue R, Yamauchim T, Miyamura K, et al. Treatment of adult T cell leukemia with mega-dose cyclophosphamide and total body irradiation followed by allogeneic bone marrow transplantation. Bone Marrow Transplant. 1987;2:441–4.PubMedGoogle Scholar
  12. 12.
    Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001;27:15–20.CrossRefPubMedGoogle Scholar
  13. 13.
    Hematopoietic Cell Transplantation in Japan. Annual Report of Nationwide Survey 2014. The Japanese Data Center for Hematopoietic Cell Transplantation/The Japan Society for Hematopoietic Cell Transplantation 2015, March 15, 2015.Google Scholar
  14. 14.
    Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:367–9.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    LYMPHOMA STUDY GROUP (1984–1987). Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study. Leuk Res. 1991;15:81–90.CrossRefGoogle Scholar
  17. 17.
    Utsunomiya A, Ishida T, Inagaki A, et al. Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor. Leuk Res. 2007;31:915–20.CrossRefPubMedGoogle Scholar
  18. 18.
    Tsukasaki K, Tobinai K. Clinical trials and treatment of ATL. Leuk Res Treat. 2012;2012:101754.Google Scholar
  19. 19.
    Katsuya H, Yamanaka T, Ishitsuka K, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012;30:1635–40.CrossRefPubMedGoogle Scholar
  20. 20.
    Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2011;116:1369–76.CrossRefGoogle Scholar
  21. 21.
    Shigematsu A, Kobayashi N, Yasui H, et al. High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia. Biol Blood Marrow Transplant. 2014;20:801–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Kawada H, Yoshimitsu M, Nakamura D, et al. A retrospective analysis of treatment outcomes in adult T cell leukemia/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: a single-center experience. Biol Blood Marrow Transplant. 2015;21:696–700.CrossRefPubMedGoogle Scholar
  23. 23.
    Tokunaga M, Uto H, Takeuchi S, et al. Newly identified poor prognostic factors for adult T-cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation. Leuk Lymhoma. 2017; 58: 37–44.Google Scholar
  24. 24.
    Okamura J, Utsunomiya A, Tanosaki R, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood. 2005;105:4143–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Ishida T, Hishizawa M, Kato K, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood. 2012;120:1734–41.CrossRefPubMedGoogle Scholar
  26. 26.
    Nakamura T, Oku E, Nomura K, et al. Unrelated cord blood transplantation for patients with adult T-cell leukemia/lymphoma: experience at a single institute. Int J Hematol. 2012;96:657–63.CrossRefPubMedGoogle Scholar
  27. 27.
    Fukushima T, Itonaga H, Moriuchi Y, et al. Feasibility of cord blood transplantation in chemosensitive adult T-cell leukemia/lymphoma: a retrospective analysis of the Nagasaki Transplantation Network. Int J Hematol. 2013;97:485–90.CrossRefPubMedGoogle Scholar
  28. 28.
    Fuji S, Fujiwara H, Nakano N, et al. Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma. Bone Marrow Transplant. 2016; 51: 205–11.Google Scholar
  29. 29.
    Yamasaki R, Miyazaki Y, Moriuchi Y, et al. Small number of HTLV-1-positive cells frequently remains during complete remission after allogeneic hematopoietic stem cell transplantation that are heterogeneous in origin among cases with adult T-cell leukemia/lymphoma. Leukemia. 2007;21:1212–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Choi I, Tanosaki R, Uike N, et al. Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma: results of prospective trials. Bone Marrow Transplant. 2011;46:116–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Yonekura K, Utsunomiya A, Takatsuka Y, et al. Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41:1029–35.CrossRefPubMedGoogle Scholar
  32. 32.
    Harashima N, Kurihara K, Utsunomiya A, et al. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res. 2004;64:391–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Itonaga H, Tsushima H, Taguchi J, et al. Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience. Blood. 2013;121:219–25.CrossRefPubMedGoogle Scholar
  34. 34.
    Ishida T, Joh T, Uike N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837–42.CrossRefPubMedGoogle Scholar
  35. 35.
    Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169:672–82.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Fuji S, Inoue Y, Utsunomiya A, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016; 34: 3426–33.Google Scholar
  37. 37.
    Wiseman DH. Donor cell leukemia: a review. Biol Blood Marrow Transplant. 2011;17:771–89.CrossRefPubMedGoogle Scholar
  38. 38.
    Matsunaga T, Murase K, Yoshida M, et al. Donor cell derived myeloid leukemia after allogeneic cord blood transplantation in a patient with adult T-cell lymphoma. Am J Hematol. 2005;79:294–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Tamaki H, Matsuoka M. Donor-derived T-cell leukemia after bone marrow transplantation. New Engl J Med. 2006;354:1758–9.CrossRefPubMedGoogle Scholar
  40. 40.
    Nakamizo A, Akagi Y, Amano T, et al. Donor-derived adult T-cell leukaemia. Lancet. 2011;377:1124.CrossRefPubMedGoogle Scholar
  41. 41.
    Hoshida Y, Li T, Dong Z, et al. Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer. 2001;91:869–75.CrossRefPubMedGoogle Scholar
  42. 42.
    Yoshizumi T, Shirabe K, Ikegami T, et al. Impact of human T cell leukemia virus type 1 in living donor liver transplantation. Am J Transplant. 2012;12:1479–85.CrossRefPubMedGoogle Scholar
  43. 43.
    Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers. Blood. 2010;116:1211–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Kozako T, Yoshimitsu M, Fujiwara H, et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia. 2009;23:375–82.CrossRefPubMedGoogle Scholar
  45. 45.
    Nishikawa H, Maeda Y, Ishida T, et al. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. Blood. 2012;119:3097–104.CrossRefPubMedGoogle Scholar
  46. 46.
    Suehiro Y, Hasegawa A, Iino T, et al. Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study. Br J Haematol. 2015;169:356–67.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan KK 2017

Authors and Affiliations

  1. 1.Department of HematologyImamura Bun-in HospitalKagoshimaJapan

Personalised recommendations